|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||23.50 - 24.67|
|52 Week Range||17.19 - 30.14|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||24.45|
|Earnings Date||Feb 13, 2023 - Feb 17, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.20|
Subscribe to Yahoo Finance Plus to view Fair Value for CORT
In this article we are going to estimate the intrinsic value of Corcept Therapeutics Incorporated ( NASDAQ:CORT ) by...
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Durect (DRRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.